Korean J Clin Neurophysiol.  2015 Dec;17(2):45-52. 10.14253/kjcn.2015.17.2.45.

Clinical and Electrophysiologic Characteristics of Paraproteinemic Neuropathy

• Pyun SY
• Kim BJ

• KMID: 2403238
• DOI: http://doi.org/10.14253/kjcn.2015.17.2.45

Abstract

The paraproteinemia is a disorder in which a single clone of plasma cells (monoclonal gammopathy) is responsible for the proliferation of monoclonal proteins (M-proteins). Approximately 10% of patients with idiopathic peripheral neuropathy have monoclonal gammopathy. Some M-proteins have the properties of an antibody to the components of peripheral nerve myelin, but the pathophysiological relationship between the neuropathy and the M-protein is often obscure. The relationship between peripheral neuropathy and monoclonal gammopathy requires the appropriate neurological and hematological investigations for precise diagnosis and treatment. In this review, we provide an update on the causal associations between peripheral neuropathy and monoclonal gammopathy as well as characteristics of clinical and electrophysiologic features.

Keyword

Paraproteinemic neuropathy; Monoclonal gammopathy; Polyneuropathy; Diagnosis; Treatment

MeSH Terms

Clone Cells
Diagnosis
Humans
Myelin Sheath
Paraproteinemias
Peripheral Nerves
Peripheral Nervous System Diseases
Plasma Cells
Polyneuropathies

Reference

1.Kyle RA. Monoclonal gammopathy of undetermined significance. Blood Rev. 1994. 8:135–141.

2.Vladutiu AO. Prevalence of M-proteins in serum of hospitalized patients. Physicians' response to finding M-proteins in serum protein electrophoresis. Ann Clin Lab Sci. 1987. 17:157–161.

3.Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program. 2005. 340–345.

4.Kelly JJ Jr., Kyle RA., O'Brien PC., Dyck PJ. Prevalence of mono-clonal protein in peripheral neuropathy. Neurology. 1981. 31:1480–1483.

5.Raheja D., Specht C., Simmons Z. Paraproteinemic neuropathies. Muscle Nerve. 2015. 51:1–13.

6.Sobol U., Stiff P. Neurologic aspects of plasma cell disorders. Handb Clin Neurol. 2014. 120:1083–1099.

7.Mauermann ML. Paraproteinemic neuropathies. Continuum (Min-neap Minn). 2014. 20:1307–1322.

8.Ramchandren S., Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012. 12:102–110.

9.El-Difrawy MM., Zaki NE., Marouf HM., Ayad MW., Farag AM. Clinical, electrophysiological and immunological study of peripheral nerves in Egyptian patients with monoclonal gammopathies. Int J Hematol. 2012. 95:71–76.

10.Nobile-Orazio E. Update on neuropathies associated with mono-clonal gammopathy of undetermined significance (2008-2010). J Peripher Nerv Syst. 2010. 15:302–306.

11.Ramchandren S., Lewis RA. Monoclonal gammopathy and neuropathy. Curr Opin Neurol. 2009. 22:480–485.

12.Kissel JT., Mendell JR. Neuropathies associated with monoclonal gammopathies. Neuromuscul Disord. 1996. 6:3–18.

13.Braun PE., Frail DE., Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem. 1982. 39:1261–1265.

14.Landgren O. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am Soc Hematol Educ Program. 2010. 295–302.

15.Kyle RA. ‘Benign' monoclonal gammopathy. A misnomer? JAMA. 1984. 251:1849–1854.

16.Rajkumar SV., Kyle RA., Therneau TM., Melton LJ 3rd., Bradwell AR., Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005. 106:812–817.

17.Eurelings M., Notermans NC., Van de Donk NW., Lokhorst HM. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve. 2001. 24:1295–1302.

18.Forssman O., Bjorkman G., Hollender A., Englund NE. IgM-producing lymphocytes in peripheral nerve in a patient with benign monoclonal gammopathy. Scand J Haematol. 1973. 11:332–335.

19.Nobile-Orazio E., Barbieri S., Baldini L., Marmiroli P., Carpo M., Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopatho-genetic studies. Acta Neurol Scand. 1992. 85:383–390.

20.Gosselin S., Kyle RA., Dyck PJ. Neuropathy associated with mono-clonal gammopathies of undetermined significance. Ann Neurol. 1991. 30:54–61.

21.Yeung KB., Thomas PK., King RH., Waddy H., Will RG., Hughes RA, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991. 238:383–391.

22.Gorson KC., Allam G., Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997. 48:321–328.

23.Gorson KC., Ropper AH. Axonal neuropathy associated with mon-oclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry. 1997. 63:163–168.

24.Nobile-Orazio E., Manfredini E., Carpo M., Meucci N., Monaco S., Ferrari S, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994. 36:416–424.

25.Steck AJ., Murray N., Meier C., Page N., Perruisseau G. Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology. 1983. 33:19–23.

26.Niermeijer JM., Fischer K., Eurelings M., Franssen H., Wokke JH., Notermans NC. Prognosis of polyneuropathy due to IgM mono-clonal gammopathy: a prospective cohort study. Neurology. 2010. 74:406–412.

27.Nobile-Orazio E., Meucci N., Baldini L., Di Troia A., Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000. 123:710–717.

28.Chassande B., Leger JM., Younes-Chennoufi AB., Bengoufa D., Maisonobe T., Bouche P, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve. 1998. 21:55–62.

29.Simmons Z., Albers JW., Bromberg MB., Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain. 1995. 118:359–368.

30.Fazio R., Nemni R., Quattrini A., Lorenzetti I., Canal N. IgG mono-clonal proteins from patients with axonal peripheral neuropathies bind to different epitopes of the 68 kDa neurofilament protein. J Neuroimmunol. 1992. 36:97–104.

31.Stubbs EB Jr.., Lawlor MW., Richards MP., Siddiqui K., Fisher MA., Bhoopalam N, et al. Anti-neurofilament antibodies in neuropathy with monoclonal gammopathy of undetermined significance produce experimental motor nerve conduction block. Acta Neuropathol. 2003. 105:109–116.

32.Bleasel AF., Hawke SH., Pollard JD., McLeod JG. IgG monoclonal paraproteinaemia and peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1993. 56:52–57.

33.Di Troia A., Carpo M., Meucci N., Pellegrino C., Allaria S., Gemignani F, et al. Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci. 1999. 164:64–71.

34.Nemni R., Mamoli A., Fazio R., Camerlingo M., Quattrini A., Lorenzetti I, et al. Polyneuropathy associated with IgA monoclonal gammopathy: a hypothesis of its pathogenesis. Acta Neuropathol. 1991. 81:371–376.

35.Magy L., Chassande B., Maisonobe T., Bouche P., Vallat JM., Leger JM. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol. 2003. 10:677–685.

36.Notermans NC., Wokke JH., Lokhorst HM., Franssen H., van der Graaf Y., Jennekens FG. Polyneuropathy associated with mono-clonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain. 1994. 117:1385–1393.

37.Gorson KC. Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Clin Apher. 1999. 14:149–153.

38.Notermans NC., Wokke JH., van den Berg LH., van der Graaf Y., Franssen H., Teunissen LL, et al. Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy. Brain. 1996. 119:421–427.

39.Plasmati R., Pastorelli F., Cavo M., Petracci E., Zamagni E., Tosi P, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007. 69:573–581.

40.Chaudhry V., Cornblath DR., Polydefkis M., Ferguson A., Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst. 2008. 13:275–282.

41.Kosturakis AK., He Z., Li Y., Boyette-Davis JA., Shah N., Thomas SK, et al. Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density. J Clin Oncol. 2014. 32:3156–3162.

42.Richardson PG., Delforge M., Beksac M., Wen P., Jongen JL., Sezer O, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012. 26:595–608.

43.Walsh JC. The neuropathy of multiple myeloma. An electrophysiological and histological study. Arch Neurol. 1971. 25:404–414.

44.Kelly JJ Jr. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve. 1983. 6:504–509.

45.Ohi T., Kyle RA., Dyck PJ. Axonal attenuation and secondary segmental demyelination in myeloma neuropathies. Ann Neurol. 1985. 17:255–261.

46.Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011. 86:591–601.

47.Dispenzieri A. POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol. 2015. 90:951–962.

48.Sung JY., Kuwabara S., Ogawara K., Kanai K., Hattori T. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve. 2002. 26:189–193.

49.Min JH., Hong YH., Lee KW. Electrophysiological features of patients with POEMS syndrome. Clin Neurophysiol. 2005. 116:965–968.

50.Nasu S., Misawa S., Sekiguchi Y., Shibuya K., Kanai K., Fujimaki Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2012. 83:476–479.

51.Mauermann ML., Sorenson EJ., Dispenzieri A., Mandrekar J., Suarez GA., Dyck PJ, et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. J Neurol Neurosurg Psychiatry. 2012. 83:480–486.

52.Guo X., Qin X., Zhang Y., Huang C., Yu G. Electrophysiological features of POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Clin Neurosci. 2014. 21:587–590.

53.Scarlato M., Previtali SC., Carpo M., Pareyson D., Briani C., Del Bo R, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005. 128:1911–1920.

54.Arimura K. Increased vascular endothelial growth factor (VEGF) is causative in Crow-Fukase syndrome. Rinsho Shinkeigaku. 1999. 39:84–85.

55.Klein CJ., Moon JS., Mauermann ML., Zeldenrust SR., Wu Y., Dispenzieri A, et al. The neuropathies of Waldenstrom's macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci. 2011. 38:289–295.

56.Gertz MA. Waldenstrom macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013. 88:703–711.

57.Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol. 2013. 88:416–425.

58.Wang AK., Fealey RD., Gehrking TL., Low PA. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc. 2008. 83:1226–1230.

59.Kelly JJ Jr., Kyle RA., O'Brien PC., Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurology. 1979. 6:1–7.

60.Rajkumar SV., Gertz MA., Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998. 104:232–237.

61.Kyle RA., Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995. 32:45–59.